Ionis Pharmaceuticals, Inc.
Compositions for Modulating Ataxin 2 Expression

Last updated:

Abstract:

Disclosed herein are antisense compounds and methods for decreasing Ataxin 2 mRNA and protein expression. Such methods, compounds, and compositions are useful to treat, prevent, or ameliorate Ataxin 2 associated diseases, disorders, and conditions. Such Ataxin 2 associated diseases include spinocerebellar ataxia type 2 (SCA2), amyotropic sclerosis (ALS), and parkinsonism.

Status:
Application
Type:

Utility

Filling date:

4 Aug 2021

Issue date:

23 Jun 2022